Mitochondria and lipid raft-located F\textsubscript{0}F\textsubscript{1}-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine

Janny A. Villa-Pulgarín\textsuperscript{1,} Consuelo Gajate\textsuperscript{1,2,} Javier Botet\textsuperscript{3,} Alberto Jimenez\textsuperscript{3,} Nicole Justies\textsuperscript{4,} Rubén E. Varela-M\textsuperscript{1,} Álvaro Cuesta-Marbán\textsuperscript{1,} Ingrid Müller\textsuperscript{4,} Manuel Modolell\textsuperscript{4,} José L. Revuelta\textsuperscript{3,} Faustino Mollinedo\textsuperscript{1,2,}*

1 Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain, 2 Laboratory of Cell Death and Cancer Therapy, Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain, 3 Metabolic Engineering Group, Departamento de Microbiología y Genética, Universidad de Salamanca, Edificio Departamental, Campus Miguel de Unamuno, Salamanca, Spain, 4 Department of Cellular Immunology, Max-Planck-Institut für Immunbiologie und Epigenetik, Freiburg, Germany, 5 Department of Medicine, Section of Immunology, St. Mary’s Campus, Imperial College London, London, United Kingdom

☯ These authors contributed equally to this work.

* fmollin@cib.csic.es

Abstract

Background
Leishmaniasis is the world’s second deadliest parasitic disease after malaria, and current treatment of the different forms of this disease is far from satisfactory. Alkylphospholipid analogs (APLs) are a family of anticancer drugs that show antileishmanial activity, including the first oral drug (miltefosine) for leishmaniasis and drugs in preclinical/clinical oncology trials, but their precise mechanism of action remains to be elucidated.

Methodology/Principal findings
Here we show that the tumor cell apoptosis-inducer edelfosine was the most effective APL, as compared to miltefosine, perifosine and erucylphosphocholine, in killing \textit{Leishmania} spp. promastigotes and amastigotes as well as tumor cells, as assessed by DNA breakdown determined by flow cytometry. In studies using animal models, we found that orally-administered edelfosine showed a potent \textit{in vivo} antileishmanial activity and diminished macrophage pro-inflammatory responses. Edelfosine was also able to kill \textit{Leishmania} axenic amastigotes. Edelfosine was taken up by host macrophages and killed intracellular \textit{Leishmania} amastigotes in infected macrophages. Edelfosine accumulated in tumor cell mitochondria and \textit{Leishmania} kinetoplast-mitochondrion, and led to mitochondrial transmembrane potential disruption, and to the successive breakdown of parasite mitochondrial and nuclear DNA. Ectopic expression of Bcl-X\textsubscript{L} inhibited edelfosine-induced cell death in both \textit{Leishmania}...
parasites and tumor cells. We found that the cytotoxic activity of edelfosine against Leishmania parasites and tumor cells was associated with a dramatic recruitment of FOF1-ATP synthase into lipid rafts following edelfosine treatment in both parasites and cancer cells. Raft disruption and specific FOF1-ATP synthase inhibition hindered edelfosine-induced cell death in both Leishmania parasites and tumor cells. Genetic deletion of FOF1-ATP synthase led to edelfosine drug resistance in Saccharomyces cerevisiae yeast.

Conclusions/Significance

The present study shows that the antileishmanial and anticancer actions of edelfosine share some common signaling processes, with mitochondria and raft-located FOF1-ATP synthase being critical in the killing process, thus identifying novel druggable targets for the treatment of leishmaniasis.

Author summary

Leishmaniasis is a major health problem worldwide, and can result in loss of human life or a lifelong stigma because of bodily scars. According to World Health Organization, leishmaniasis is considered as an emerging and uncontrolled disease, and its current treatment is far from ideal, with only a few drugs available that could lead to drug resistance or cause serious side-effects. Here, we have found that mitochondria and raft-located FOF1-ATPase synthase are efficient druggable targets, through which an ether lipid named edelfosine exerts its antileishmanial action. Edelfosine effectively kills Leishmania spp. promastigotes and amastigotes. Our experimental animal models demonstrate that oral administration of edelfosine exerts a potent antileishmanial activity, while inhibits macrophage pro-inflammatory responses. Our results show that both Leishmania and tumor cells share mitochondria and raft-located FOF1-ATPase synthase as major druggable targets in leishmaniasis and cancer therapy. These data, showing a potent antileishmanial activity of edelfosine and unveiling its mechanism of action, together with the inhibition of the inflammatory responses elicited by macrophages, suggest that the ether lipid edelfosine is a promising oral drug for leishmaniasis, and highlight mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets for the treatment of this disease.

Introduction

Leishmaniasis, caused by several species of the protozoan Leishmania parasite, is one of the world’s most neglected diseases in terms of drug research and development, and for which current therapy is not satisfactory [1]. At present, about 350 million people in 98 countries worldwide are at risk of contracting leishmaniasis, and some 0.9–1.6 million new cases occur yearly, with about 0.7–1.2 million cases of self-healing cutaneous leishmaniasis, which can result in disfiguring skin lesions, and 0.2–0.4 million cases per year of life-threatening visceral leishmaniasis, which is a fatal disease if left untreated [1–3]. Leishmaniasis is the world’s second-deadliest parasitic disease after malaria, with a tentative estimate of 20,000 to 40,000 leishmaniasis deaths occurring annually [3], and has been classed as a category 1 disease (“emerging and uncontrolled”) by the World Health Organization (WHO). At present there are very few available
antileishmanial drugs, being in general toxic, and the first line drugs are becoming ineffective due to emerging drug resistance [1, 2]. Thus, the development of novel therapeutic drugs is urgently needed. Leishmaniasis is transmitted by the bite of a female sandfly vector (*Lutzomyia* in the Americas and *Phlebotomus* elsewhere) infected with *Leishmania* parasites. Infection of humans and other animal hosts is initiated by flagellated promastigotes that develop within the digestive tract of the sandfly vector and are injected during a sandfly blood meal. Promastigotes are internalized into a number of phagocytic host cells, including neutrophils, dendritic cells, and macrophages, but proliferate only within the macrophage as aflagellate amastigotes [4, 5].

The so-called alkylphospholipid analogs (APLs) constitute a class of structurally-related antitumor compounds with multiple therapeutic indications, and include a number of clinically relevant and/or promising drugs, such as miltefosine (hexadecylphosphocholine), edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine), perifosine (octadecyl (1,1-dimethyl-piperidinio-4-yl)-phosphate) and erucylphosphocholine ((13Z)-docos-13-en-1-yl 2-(trimethylammonio)ethyl phosphate) (ErPC) (Fig 1) [6–8]. So far, miltefosine is the only APL that has entered the clinic, registered as Impavido, the first orally-effective treatment for visceral leishmaniasis, and as Miltex, a topical chemotherapy and palliative treatment in cutaneous metastases from breast cancer [7, 9, 10]. APLs induce an apoptosis-like cell death in *Leishmania* parasites [11, 12], but their antiparasitic mechanism of action remains unknown, although lipid metabolism [13] and dramatic increases in membrane dynamics [14] have been suggested to play a role.

The ether lipid edelfosine induces apoptosis in tumor cells, involving cholesterol-rich lipid rafts and mitochondria [15–20]. Lipid rafts are membrane microdomains highly enriched in cholesterol and sphingolipids, and recent findings in mammalian cells suggest that lipid rafts act as death-promoting scaffolds, where Fas/CD95 and downstream signaling molecules are recruited to trigger apoptosis [21–23]. Raft domains have also been described in *Leishmania* spp., although their biochemical and functional characterization remains incomplete [24].
Here, we analyzed whether our knowledge on processes involved in the anticancer activity of APLs could provide some insight into their antileishmanial mechanism of action. In addition, we tested the effect of APLs on intact and *Leishmania*-infected macrophages as the main host cells for *Leishmania* parasites, as well as the *in vivo* antileishmanial activity of edelfosine in animal models. In this study, we report the existence of common mechanisms that underlie the antileishmanial and antitumor activities of the APL edelfosine, involving mitochondria, lipid rafts and F$_{0}$F$_{1}$-ATP synthase (also named as F$_{0}$F$_{1}$-ATPase), which might open up new avenues for the development of novel targeted therapies.

**Materials and methods**

**Ethics statement**

Animal procedures were approved by the institutional research commission of the University of Salamanca, and were approved by the Ethics Committee of the University of Salamanca (protocol approval number 48531). Animal procedures complied with the Spanish (Real Decreto RD1201/05) and the European Union (European Directive 2010/63/EU) guidelines on animal experimentation for the protection and humane use of laboratory animals, and were conducted at the accredited Animal Experimentation Facility (Servicio de Experimentación Animal) of the University of Salamanca (Register number: PAE/SA/001).

**Drugs and reagents**

Edelfosine was from R. Berchtold (Biochemisches Labor, Bern, Switzerland). Miltefosine was from Calbiochem (Cambridge, MA). Perifosine and erucylphosphocholine were from Zentaris (Frankfurt, Germany). Rotenone, malonate, antimycin A, azide, oligomycin and CCCP were from Sigma (St. Louis, MO).

**Cells and culture conditions**

The *Leishmania* strains used in this study were: *L. donovani* (MHOM/IN/80/DD8), *L. major* LV39 (MRHO/SU/59/P), *L. panamensis* (MHOM/CO/87/UA140), *L. infantum* (MCAN/ES/96/BCN/150, MON-1), kindly provided by Iván D. Vélez (Programa de Estudio y Control de Enfermedades Tropicales–PECET–, Medellín, Colombia), Ingrid Müller (Imperial College London, London, UK) and Antonio Jiménez-Ruiz (Universidad de Alcalá, Alcalá de Henares, Spain). To visualize *Leishmania* parasites inside macrophages we used GFP-*L. panamensis* promastigotes [25, 26]. *Leishmania* promastigotes were grown at 26°C in RPMI-1640 culture medium (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. Promastigotes were treated at 26°C with the indicated compounds during their logarithmic growth phase (1.5 x 10^6 parasites/ml). Late stationary promastigotes were obtained after incubation of the parasites for more than 6 days with a starting inoculum of 1 x 10^6 parasites/ml. *Leishmania* axenic amastigotes were obtained as previously described [27]. Human acute T-cell leukemia Jurkat (American Type Culture Collection, Manassas, VA), myeloid leukemia HL-60 (American Type Culture Collection), multiple myeloma MM144 (provided by A. Pandiella, CIC, IBMCC, Salamanca, Spain), and cervical carcinoma HeLa (American Type Culture Collection) cell lines, as well as the mouse macrophage cell line J774 (American Type Culture Collection) were grown in RPMI-1640 culture medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in humidified 95% air and 5% CO$_{2}$. 
Yeast experiments and growth conditions

*Saccharomyces cerevisiae* yeast (BY4741 strain: MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) was grown on standard synthetic complete medium (SDC), which consisted of synthetic minimal medium (SD; 0.17% yeast nitrogen base without amino acids, 2% glucose and supplements according to the requirements of the strains) with 0.079% complete supplement mixture (For-Medium, Norwich, UK). Yeast cultures were incubated at 30˚C, and growth of cells untreated or treated with edelfosine was monitored by optical density at a wavelength of 595 nm (OD\textsubscript{595}). Cells were incubated for the indicated times and sample aliquots were taken to measure absorbance at 595 nm. Edelfosine was used at the concentrations indicated in the corresponding figure in liquid medium. The *atp7Δ* mutant was obtained from the EUROSCARF haploid deletion library in the BY4741 background [28]. This *atp7Δ* mutant was complemented with the corresponding wild-type gene expressed from a centromeric plasmid (pRS416), and yeast growth was determined as above.

Bcl-X\textsubscript{L} transfection

*L. infantum* transfectected with pX63-Neo or pX63*-bcl-x\textsubscript{L}*-were kindly provided by Antonio Jiménez-Ruiz (Universidad de Alcalá, Alcalá de Henares, Spain) and grown in medium containing 100 μg/ml G418 (Sigma) [29]. HeLa cells (1–2 x 10\textsuperscript{5}) were transfected with 2 μg of pSFFV-*bcl-x\textsubscript{L}* or pSFFV-Neo expression vector [15], using Lipofectin reagent (Life Technologies, Carlsbad, CA). Transfected clones were selected by growth in the presence of 500 μg/ml G418, and monitored by Western blotting using the 2H12 anti-29 kDa Bcl-X\textsubscript{L} monoclonal antibody (BD Biosciences PharMingen, San Diego, CA).

Generation of mouse bone marrow-derived macrophages (BMM)

Murine bone marrow cells were obtained by flushing out the femurs of mice from (C57BL/6 x BALB/c)F1 (CBF1) mice and cultured as previously described [30] in hydrophobic Teflon bags (Biofolie 25, Heraeus, Hanau, Germany) with DMEM culture medium containing 10% FBS, 5% horse serum, 2 mM L-glutamine, 60 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 1% non-essential amino acids, 100 U/ml penicillin, 100 μg/ml streptomycin, and the supernatant of L929 fibroblasts at a final concentration of 15% (v/v) as a source of colony-stimulating factors which drive cells towards a >95% pure BMM [31].

BMM obtained from edelfosine-treated mice

CBF1 mice were treated orally with edelfosine (5 mg/kg body weight), daily for 13 days in 100 μl PBS, and then BMM were prepared as above. No weight loss or other visible side-effects were observed in mice treated with edelfosine.

Macrophage cell viability assay

Cell viability at the indicated times was measured by the WST-1 reduction to formazan method (Roche Diagnostics, Basel, Switzerland). 10\textsuperscript{5} cells were incubated for 2 h at 37˚C with 10 μl WST-1 solution in 0.2 ml DMEM culture medium supplemented with 10% FBS in a flat-bottom microtitre plate, and then absorbance was determined at 440 nm.

Determination of superoxide anion

The production of superoxide anion (2 x 10\textsuperscript{5} cells in 0.2 ml Hepes-DMEM without pH indicator and containing 125 μM lucigenin, 37˚C) was initiated by addition of 50 μg zymosan, and
measured as lucigenin-dependent chemiluminescence using a Microlumat LB96P (Berthold, Wildbad, Germany) [32].

Nitric oxide (NO) determination
NO end product nitrite was measured using the Griess reagent as previously described [32]. Culture supernatant was mixed with 100 μl of 1% sulphanilamide, 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride and 2.5% H₃PO₄. Absorbance was measured at 540 nm in a microplate reader (Molecular Devices, Ismaning, Germany). LPS from S. abortus equi was kindly provided by Chris Galanos (Max-Planck-Institut, Freiburg, Germany).

IFN-γ assay
IFN-γ was determined by a commercially available (Pharmingen) sandwich ELISA test according to the manufacturer’s protocol.

Determination of intracellular ATP level
The ATP content was determined by the luciferin–luciferase method [33]. The assay is based on the requirement of luciferase for ATP in producing light (emission maximum 560 nm at pH 7.8). Briefly, cells (2 x 10⁶) were harvested after treatment, resuspended in 1X PBS, and assayed for ATP using the Molecular Probes ATP determination kit (Thermo Fisher Scientific, Waltham, MA). The amount of ATP in each experimental sample was calculated from a standard curve prepared with ATP and expressed as percentage of the amount of ATP found in untreated control cells.

Analysis of apoptosis-like cell death by flow cytometry
1.5 x 10⁶ Leishmania spp. promastigotes or axenic amastigotes, and 10⁶ Jurkat cells or other human cells were incubated in the absence or presence of the indicated concentrations of APLs for different incubation times, and then analyzed for DNA breakdown by flow cytometry, using a fluorescence-activated cell sorting (FACS)Calibur flow cytometer (Becton Dickinson, San Jose, CA), as previously described [16]. Quantitation of apoptotic-like cells was monitored following cell cycle analysis as the percentage of cells in the sub-G₀/G₁ region, representing hypodiploids or apoptotic-like cells [16].

Cytofluorimetric analysis of mitochondrial transmembrane potential (ΔΨₘ) and generation of reactive of oxygen species (ROS)
2 x 10⁶ Leishmania parasites and 10⁶ Jurkat cells were pelleted by centrifugation, washed with PBS, incubated in 1 ml PBS containing 20 nM 3,3'-dihexyloxacarbocyanine iodide (DiOC₆(3), green fluorescence; Molecular Probes, Leiden, The Netherlands) and 2 μM dihydroethidine (HE, red fluorescence after oxidation; Sigma) at room temperature and darkness for 20 min, and then analyzed on a Becton Dickinson FACSCalibur flow cytometer as previously described [16].

Macrophage infection
Macrophages, cultured in RPMI 1640 culture medium containing 10% FBS, were incubated for 4 h with stationary-phase L. panamensis promastigotes at a 10:1 parasite-to-macrophage ratio. Then, cell monolayers were extensively washed and incubated in complete culture medium with or without edelfosine for 24 h. The intracellular parasite load was calculated by limiting dilution assay as previously reported [34]. Alternatively, macrophage monolayers infected with green fluorescent protein (GFP)-expressing p6.5-eGFP-L. panamensis parasites
were cultured in glass coverslips placed into culture vessels (Corning, Lowell, MA). After 24 h, coverslips were washed, and the rate of intracellular amastigotes and infected macrophages was visualized using a fluorescence microscope. Results are shown as the percentage of infected macrophages and as the parasite/macrophage ratio after counting 100 macrophages.

**In vivo antileishmanial activity**

Four-week-old male Syrian golden hamsters (*Mesocricetus auratus*) (about 120 g) were obtained from Charles River Laboratories (Lyon, France) and maintained in a pathogen-free facility. Animals were handled according to institutional guidelines, complying with the Spanish legislation, in an animal room with 12-h light/dark cycle at a temperature of 22˚C, and received a standard diet and water *ad libitum*. Hamsters were inoculated intradermally in the nose with 1 x 10^6 stationary-phase promastigotes in a volume of 50 μl PBS and treated with a daily oral administration of edelfosine (20 mg/kg in water), or an equal volume of vehicle (water) as previously described [26]. Nose swelling was evaluated through weekly caliper measurements, and compared with the nose size before inoculation and treatment. Evolution index of the lesion was calculated as the size (mm) of the lesion during treatment/size of the lesion before treatment. No loss in animal body weight and no sign of morbidity were detected during the 28-day drug treatment, and animals were killed, following institutional guidelines, 24 h after the last drug administration. Parasite burden in the infected tissues was calculated by limiting dilution assay as previously described [26].

**TUNEL assay**

Apoptosis-like cell death was also analyzed *in situ* by the TUNEL technique using the Fluorescein Apoptosis Detection System (Promega, Madison, WI), according to the manufacturer’s instructions. Parasites were fixed with 4% formaldehyde for 20 min on microscope slides, permeabilized with 0.2% Triton X-100, stained for fragmented DNA using the above kit, and then propidium iodide was added for 15 min to stain both apoptotic-like and intact cells as previously described [17, 35, 36]. Propidium iodide stained all cells in red, whereas fluorescein-12-dUTP was incorporated at the 3’-OH ends of fragmented DNA, resulting in localized green fluorescence within the nucleus of apoptotic-like cells. Samples were analyzed with a Zeiss LSM 510 laser scan confocal microscope (Carl Zeiss AG, Jena, Germany).

**Edelfosine localization by fluorescence microscopy**

*L. panamensis* and HeLa cells were treated for 1 h with 10 μM fluorescent edelfosine analog all-(E)-1-O-(15’-phenylpentadeca-8’,10’,12’,14’-tetraenyl)-2-O-methyl-rac-glycero-3-phosphocholine (PTE-ET) (Fig 1), kindly provided by F. Amat-Guerri and A.U. Acuña (Consejo Superior de Investigaciones Científicas, Madrid, Spain) as described [17, 36, 37], and then incubated with 100 nM cell-permeant MitoTracker probe (Molecular Probes) for 20 min to label mitochondria. Colocalization was analyzed by excitation of the corresponding fluorochromes in the same section of samples, using a fluorescence microscope (Axioplan 2; Carl Zeiss MicroImaging, Inc., Oberkochen, Germany) and a digital camera (ORCA-ER-1394; Hamamatsu, Hamamatsu City, Japan).

**Disruption of lipid microdomains in Leishmania promastigotes and Jurkat cells**

Parasites (2 x 10⁶/ml) were incubated in serum-free medium with 2.5 mg/ml methyl-β-cyclo-dextrin (MCD) for 40 min at 26˚C, and then washed 3 times with PBS, and resuspended in
complete culture before edelfosine addition. For cholesterol depletion in Jurkat cells, 2.5 x 10^5 cells/ml were incubated with 2.5 mg/ml MCD for 30 min at 37˚C in serum-free medium, and then washed 3 times with PBS, and resuspended in complete culture before edelfosine addition.

**Edelfosine uptake**

Drug uptake was measured as previously described [15, 36], after incubating 2 x 10^6 parasites or 10^6 Jurkat cells with 10 nmol [^3H]edelfosine (10 μM) (Amersham Buchler, Braunschweig, Germany) for 1 h in RPMI-1640, 10% FBS, and subsequent washing (six times) with PBS + 2% BSA. [^3H]edelfosine (specific activity, 42 Ci/mmol) was synthesized by tritiation of the 9-octadecenyl derivative (Amersham Buchler, Braunschweig, Germany).

**Lipid raft isolation**

Lipid rafts were isolated from 1 x 10^8 Leishmania promastigotes or 8 x 10^7 Jurkat cells by using nonionic detergent lysis conditions and centrifugation on discontinuous sucrose gradients as previously reported [38, 39]. Twelve 1-ml fractions were collected from the top of the gradient, and 25 μl of each fraction were subjected to sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and assayed for the location of GM1-containing lipid rafts using the GM1-specific ligand cholera toxin (CTx) B subunit conjugated to horseradish peroxidase (Sigma, St. Louis, MO).

**Two-dimensional gel electrophoresis**

The proteomic analysis was performed in the proteomics facility of Centro de Investigación del Cáncer (CIC), Salamanca, Spain, which belongs to ProteoRed, PRB2-ISCIII. Samples (100 μg protein) from pooled fractions enriched in lipid rafts (fractions 3–6 from the sucrose gradient) were precipitated with methanol/chloroform, and then the pellets were resuspended in rehydration buffer (7 M urea, 2M thiourea, 4% CHAPS, 50 mM DTT, 5 mM TCEP, 15 mg DeStreak, 0.5% IPG buffer). Samples were applied to 13 cm IPG strips with a nonlinear pH gradient of 3 to 10 (Amersham Biosciences). Isoelectric focusing was performed at 50 V for 12 hours, 500 V for 1 h, 1000 V for 1 h, a voltage gradient ranging from 1000 to 8000 V for 30 min, and finally 5 h until the voltage reached 35000 V. Strips were treated with SDS equilibration buffer (375 mM Tris-HCl pH 8.8, 6 M urea, 20% glycerol, 2% SDS) plus 2% DTT for 15 min for protein denaturation, and then with equilibration buffer plus 2.5% iodoacetamide for protein alkylation. The second dimension electrophoresis was performed on 10% SDS-polyacrylamide gels. The protein spots were visualized with Sypro Ruby Protein Gel Staining (Invitrogen, Carlsbad, CA).

**Spot excision, tryptic digestion of proteins, mass determination and protein identification**

Spots of interest were automatically excised with Proteineer Spot Picker robotics workstation (Bruker Daltonics, Billerica, MA). The digestion was performed as previously described [40]. For MALDI-TOF peptide mass fingerprinting, a 0.5 μl aliquot of matrix solution (5 g/l 2.5-dihydroxybenzoic acid in 33% aqueous acetonitrile plus 0.1% trifluoroacetic acid) was manually loaded onto a 400 μm diameter AnchorChip Target plate (Bruker Analytic GmbH, Bremen, Germany) probe, and 1 μl of the above peptide extraction solution was added and allowed to dry at room temperature. Samples were analyzed on a Bruker Ultraflex MALDI-TOF mass spectrometer (Bruker-Franzen Analytic GmbH, Bremen, Germany). Each raw
spectrum was opened in FlexAnalysis 3.0 (Bruker Daltonics) software and processed and analyzed using the following parameters: signal-to-noise threshold of 1, Savitzky-Golay algorithm for smoothing, tangential algorithm for baseline subtraction, and centroid algorithm for monoisotopic peak assignment. In all cases, resolution was higher than 9000. The generated peaks were submitted to Mascot Server (version 2.2, February 2007) [41] using Bio Tools 3.1 (Bruker Daltonics) software, and searched against Uniprot database for human sequences and NCBI database for *Leishmania* sequences. Search parameters were set as follow: searches were restricted to all sequences for human searches and Other Eukaryota (69482 sequences) for *Leishmania* searches, up to one missed tryptic cleavage, mass accuracy of 100 ppm, MH+ monoisotopic masses, carbamidomethyl cysteine as fixed modification, and methionine oxidation as variable modification. Mowse scores with a value greater than 65 for human searches and 61 for *Leishmania* searches were considered as significant (*p* < 0.05).

Statistical analysis

Data are shown as mean ± SD. Between-group statistical differences were assessed using the Student’s *t* test. A *P*-value of < 0.05 was considered statistically significant.

Results

Differential capacity of APLs in promoting cell death in *Leishmania* spp. and human cancer cells with apoptosis-like characteristics

First we analyzed the ability of different APLs (Fig 2A and 2B) in promoting apoptosis-like cell death in different *Leishmania* spp. promastigotes and human cancer cell lines, as assessed by DNA breakdown determined by flow cytometry. Our results showed that APLs ranked edelfosine > miltefosine > perifosine > erucylphosphocholine (ErPC) for their leishmanicidal activity (Fig 2A), and edelfosine > perifosine > miltefosine ≡ erucylphosphocholine (ErPC) for their antitumor activity (Fig 2B), when incubated for 24 h at 10 μM with several *Leishmania* spp. promastigotes, including *L. donovani* (visceral leishmaniasis), *L. panamensis* (cutaneous and mucocutaneous leishmaniasis), and *L. major* (cutaneous leishmaniasis), or with human cancer cell lines, including myeloid leukemia HL-60 cells, multiple myeloma MM144 cells, and cervical cancer HeLa cells. This drug concentration (10 μM) corresponded to the pharmacologically relevant concentration range of edelfosine in plasma (10–20 μM), previously determined in a number of *in vivo* and pharmacokinetic studies [19, 42, 43]. We also found that edelfosine was very efficient in promoting cell death in additional human leukemic cell lines, including human T-cell acute lymphoblastic leukemia (T-ALL) cell lines Jurkat (53.4 ± 6.2% apoptosis) and CEM-C7H2 (58.2 ± 5.9% apoptosis). Edelfosine was equally effective against different *Leishmania* subgenera, including *Leishmania* *Leishmania* (*L. donovani*, *L. major*) and *Leishmania* *Viannia* (*L. panamensis*) (Fig 2A). The relative difference between the abilities to promote cell death of edelfosine vs. miltefosine was more evident using tumor cells than *Leishmania* spp. promastigotes, suggesting that processes involved in the mechanisms of action of both drugs are partially conserved, but not identical. For the ensuing studies, we focused our attention on the most effective compound, namely edelfosine, which has been considered as the APL prototype. Edelfosine induced DNA breakdown after 9-h incubation with *L. panamensis* promastigotes, and the percentage of parasites with a hypodiploid DNA content (sub-G₀/G₁ cell population) increased with the incubation time (Fig 2C), suggesting an apoptosis-like cell death in *Leishmania* parasites, similar to the apoptotic response triggered in cancer cells [15, 17, 35, 44]. Edelfosine (5 or 10 μM) also induced apoptosis-like cell death, as assessed by an increase in the sub-G₀/G₁ population, in *L. panamensis* axenic amastigotes (Fig 2D).
Edelfosine accumulates into and kills *Leishmania* amastigotes in infected macrophages

Because *Leishmania* are obligate intracellular parasites that infect macrophages within the mammalian host, we examined the location of edelfosine in *L. panamensis*-infected J774 macrophage-like cells. We have previously found that mouse *J774* macrophages were rather...
resistant to edelfosine [26], and 10 μM edelfosine was unable to mount an apoptotic response after 24-h incubation (<2.5% apoptosis). Using the blue-emitting fluorescent edelfosine analog PTE-ET (Fig 1), a bona fide compound to explore the subcellular localization of edelfosine [17, 19, 36, 37, 45], we found that it was mainly located into the parasites inside the macrophage (Fig 2E), which were visualized by using infective GFP- *L. panamensis* parasites [25]. Edelfosine treatment highly diminished the amount of infected J774 macrophages and the number of parasites per macrophage (Fig 2F and 2G). Following limiting dilution experiments, we found that edelfosine was the most effective APL, when compared to miltefosine, perifosine and erucylphosphocholine (ErPC), in killing *L. major* amastigotes in infected mouse BMM (Fig 2H). Edelfosine was highly dependent on its molecular structure for its antileishmanial activity, since a structurally related compound, ET-18-OH (1-O-octadecyl-rac-glycerol-3-phosphocholine) (Fig 1), containing a hydroxyl group instead of the methoxy group at the C2 position, was unable to kill *Leishmania* protozoa (Fig 2H), similarly to what has been found in cancer cells [15, 44].

**In vivo antileishmanial activity of edelfosine**

We have previously shown the potent antitumor activity of orally-administered edelfosine in different xenograft animal models [19, 43, 46]. Recently, we have also found that edelfosine was effective in the treatment of leishmaniasis in different animal models when used at 26 mg/kg body weight [26]. Here, we found that oral treatment of edelfosine at a lower dose (20 mg/kg body weight) exerted a potent in vivo antileishmanial activity in *L. panamensis*-infected golden hamsters (Fig 2I–2K), an appropriate animal model for reproducing the pathological features of human leishmaniasis [47]. *L. panamensis* promastigotes were inoculated into the nose of 16 golden hamsters, and then animals were randomly distributed into two cohorts of eight hamsters. Each cohort received a daily oral administration of edelfosine or water vehicle (control) for 28 days. Disease progression was monitored by nasal swelling, determined by serial caliper measurements, and ulceration. Oral treatment with edelfosine led to a dramatic decrease in nasal swelling and parasite load at the site of infection (Fig 2I–2K), and ameliorated the signs of leishmaniasis, leading to an almost normal morphologic appearance (Fig 2K).

**Edelfosine is taken up by macrophages and inhibits the generation of macrophage-derived pro-inflammatory mediators**

Edelfosine has been shown to be taken up preferentially by tumor cells, whereas normal non-malignant cells incorporated a relatively much lesser amount of the ether lipid [15, 17, 35]. Here, we found that normal mouse BMM took up large amounts of edelfosine, at even higher levels than the mouse RAW 309 Cr.1 tumor macrophage cell line (Fig 3A). However, edelfosine induced cell death in the transformed macrophage cell line, but spared BMM (Fig 3B). Interestingly, edelfosine blocked zymosan-induced respiratory burst in BMM (Fig 3C). Furthermore, BMM from mice that were orally treated with edelfosine (5 mg/kg body weight, daily) for two weeks showed a lower capacity to generate superoxide anion, NO and IL-12+IL-18-induced IFN-γ, when compared to BMM from mice treated with water vehicle (Fig 3D–3F). These results suggest that edelfosine treatment decreases macrophage pro-inflammatory responses. Our data, together with the above accumulation of edelfosine into the parasites in *Leishmania*-infected macrophages, suggest that edelfosine-induced killing of *Leishmania* is mediated by a direct action of the drug on the parasite, and not via generation of macrophage-derived antiparasitic molecules.
Edelfosine induces kinetoplast DNA cleavage prior to nuclear DNA breakdown

DNA breakdown induced by edelfosine treatment in *Leishmania* was further assessed by the TUNEL assay, staining all cells in red through the binding of propidium iodide to DNA, and only those cells with fragmented DNA and free 3'-OH ends in green. Interestingly, we detected first kinetoplast-mitochondrial DNA degradation, followed by nuclear DNA fragmentation upon treatment of *L. panamensis* promastigotes with edelfosine (Fig 4A). These results suggest that the death process induced by edelfosine in *Leishmania* spp. parasites starts at the mitochondrial level.

Edelfosine accumulates in the mitochondria of *Leishmania* and cancer cells

Next, we analyzed the subcellular localization of edelfosine in *Leishmania* promastigotes. The fluorescent edelfosine analog PTE-ET, which has been previously shown to fully mimic the...
Edelfosine induces breakage of kinetoplast DNA prior to nuclear DNA breakdown, and accumulates in mitochondria in *Leishmania* parasites and cancer cells.

**A**

*L. panamensis* promastigotes were untreated (Control) or treated with 10 μM edelfosine (EDLF) for 6 and 9 h, and then analyzed by confocal microscopy for propidium iodide (PI) staining and TUNEL assay. The positions of the nucleus (N) and kinetoplast (K) are indicated by arrows. Merging of PI and TUNEL panels (Merge) shows the DNA-containing organelles with DNA disruption in yellow. The corresponding differential interference contrast (DIC) images were included in the Merge panels to highlight parasite morphology and facilitate kinetoplast identification.

**B**

DIC, MitoTracker, PTE-ET, and Merge panels show raft-located 

**C**

DIC, MitoTracker, PTE-ET, and Merge panels show raft-located
antitumor [17, 19, 36, 37, 45, 48] and antileishmanial [49] actions of the parent drug edelfosine, accumulated mainly in the mitochondria of *L. panamensis* promastigotes, as indicated by colocalization with the specific mitochondrial marker MitoTracker (Fig 4B). PTE-ET also co-localized with MitoTracker-positive structures in human cervical carcinoma HeLa cells (Fig 4C).

**Mitochondrial involvement in edelfosine-induced *Leishmania* death**

We next examined the time-course of the effect of edelfosine on the following mitochondrial-related processes in *L. panamensis* promastigotes: a) ROS generation, through the conversion of non-fluorescent dihydroethidine (HE) into red fluorescent ethidium (Eth) after its oxidation via ROS; and b) changes in ΔΨ_m, through the accumulation of the fluorescent cationic probe DiOC6(3) (green fluorescence), which depends on the mitochondrial potential. As shown in Fig 5A, untreated parasites exhibited a high ΔΨ_m [(DiOC6(3))<sup>high</sup>], and the levels of intracellular ROS were undetectable [(HE → Eth)<sup>low</sup>]. Edelfosine induced first an increase in the percentage of cells with (HE → Eth)<sup>high</sup>, and then a loss in ΔΨ_m (Fig 5A). Changes in ROS generation and ΔΨ_m disruption apparently preceded DNA breakdown. Edelfosine induced Eth staining, i.e. ROS generation, in kinetoplasts, as assessed by using DNA staining to identify *L. panamensis* nuclei and kinetoplasts (mitochondrial DNA) (Fig 5B). The inhibitor of the mitochondrial permeability transition pore cyclosporin A [50], and the antioxidant agents glutathione (GSH) and N-acetylcysteine (NAC), inhibited edelfosine-induced cell death in *L. panamensis* promastigotes (Fig 5C). Likewise, cyclosporin A, GSH and NAC inhibited edelfosine-induced apoptosis in human T-cell leukemia Jurkat cells (Fig 5D). Taken together, our data suggest a critical role of mitochondria in the antileishmanial and antitumor activities of edelfosine, and that both ROS generation and ΔΨ_m disruption are involved in edelfosine-induced cell death in *Leishmania* parasites and human cancer cells.

**Effects of respiration inhibitors and uncouplers on edelfosine-induced ROS generation in *Leishmania* and tumor cells**

We next examined whether the mitochondrial respiration chain was involved in edelfosine-induced ROS production, by using the following mitochondrial respiration inhibitors: rotenone, complex I inhibitor; malonate, complex II inhibitor; antimycin A, complex III inhibitor; azide, complex IV inhibitor; oligomycin, mitochondrial F<sub>0</sub>F<sub>1</sub>-ATP synthase inhibitor; and carbonyl cyanide m-chlorophenyl hydrazone (CCCP), one of the most frequently used uncouplers of oxidative phosphorylation [51]. Incubation of cells with CCCP, which disrupts the proton gradient by carrying protons across the mitochondrial membrane and causes mitochondrial depolarization, prompted the generation of ROS in *L. panamensis* and Jurkat cells, and increased edelfosine-induced ROS generation (Fig 5E and 5F). Incubation of *L. panamensis* and Jurkat cells for 9 h with rotenone, malonate, antimycin A or azide, affecting the electron transport at specific sites, neither promoted ROS generation nor affected edelfosine-mediated ROS production significantly (Fig 5E and 5F). In contrast, oligomycin, a specific inhibitor of the membranous proton channel (F<sub>O</sub>) of mitochondrial F<sub>0</sub>F<sub>1</sub>-ATP synthase [52], reduced ROS production levels induced by edelfosine in *L. panamensis* and Jurkat cells (Fig 5E and 5F). Lower concentrations of oligomycin in *L. panamensis* (1 μM) as compared to Jurkat cells (10
Fig 5. Involvement of mitochondria and ROS generation in edelfosine-induced cell death in *Leishmania* parasites and cancer cells. (A) *L. panamensis* promastigotes were untreated (Control) or treated with 10 μM edelfosine at the indicated times, and cells with disrupted ΔΨm (DiOC6(3)low) and ROS production (HE→Eth) were measured by flow cytometry. The numbers in each quadrant refer to the percentages of cells in each population. (B) *L. panamensis* promastigotes untreated (Control) and treated with edelfosine (EDLF) for 3 h were incubated with 2 μM HE and 10 μg/ml Hoechst 33342, and then analyzed by fluorescence microscopy. (C) *L. panamensis* promastigotes and (D) Jurkat cells were preincubated with 10 μg/ml CsA for 1 h, or with 10 mM NAC or 10 mM GSH for 2 h, and then incubated in the absence or presence of 10 μM edelfosine for 9 h. After treatment, the percentage of hypodiploid cells was analyzed by flow cytometry. Untreated control cells were run in parallel. (E) *L. panamensis* promastigotes and (F) Jurkat cells were preincubated with 10 μM rotenone, 5 mM malonate, 10 μM antimycin A, 1.5 mM azide, 50 μM CCCP or with 1 and 10 μM oligomycin (*L. panamensis* and Jurkat cells, respectively) for 1 h, and then incubated in the absence or presence of 10 μM edelfosine for 9 h. After treatment, cells producing ROS were quantified by flow cytometry. Untreated control cells were run in parallel. Data shown are means ± SD or representative of three independent experiments performed. Asterisks denote that the differences between
μM) were used, because *Leishmania* parasites were very sensitive to higher concentrations of oligomycin, resulting in cytotoxicity. Thus, our data suggest that F$_{0}$F$_{1}$-ATP synthase plays a role in edelfosine-mediated ROS production in both *Leishmania* and tumor cells, a process that eventually leads to cell death.

**Bcl-X$_L$ inhibits cell death in *Leishmania* and tumor cells**

In order to generalize and further support the role of mitochondria in edelfosine-induced cell death in *Leishmania* parasites and tumor cells, *L. infantum* and HeLa cells stably transfected with the expression vectors pX63-Neo (*Leishmania*) and pSFFV-Neo (HeLa), containing the human bcl-x$_L$ open reading frame (pX63-bcl-x$_L$ and pSFFV-bcl-x$_L$, respectively), were used. *L. infantum* and HeLa cells transfected with control empty pX63-Neo and pSFFV-Neo plasmids, respectively, were used as controls and behaved similarly to wild-type nontransfected *Leishmania* promastigotes and tumor cells, regarding edelfosine-induced cell death (Table 1). We found that Bcl-X$_L$ ectopic expression in *L. infantum* promastigotes and HeLa tumor cells inhibited the percentage of hypodiploid cells following edelfosine treatment (Table 1), further supporting the critical role of mitochondria in the induction of apoptosis-like cell death in *Leishmania* and tumor cells treated with edelfosine. The concentration of edelfosine was increased to 40 μM in the case of *L. infantum* promastigotes as they were rather resistant to APL treatment [26]. Taken together, these assays support a crucial role of mitochondria in the killing activity of edelfosine on *Leishmania* parasites.

**Table 1. Inhibition of apoptosis-like cell death by ectopic expression of Bcl-X$_L$ in *L. infantum* promastigotes and HeLa tumor cells.**

| Cells                        | % Hypodiploid cells |
|------------------------------|----------------------|
|                               | Control | Edelfosine |
| *L. infantum* (wild type)    | 1.9 ± 0.5 | 25.3 ± 2.1 |
| *L. infantum*-pX63           | 2.1 ± 0.7 | 27.8 ± 2.5 |
| *L. infantum*-Bcl-X$_L$      | 2.0 ± 0.5 | 11.7 ± 2.0* |
| HeLa (wild type)             | 2.8 ± 0.7 | 35.1 ± 2.7 |
| HeLa-pSFFV                   | 3.3 ± 0.9 | 38.5 ± 3.2 |
| HeLa-Bcl-X$_L$               | 3.1 ± 0.8 | 4.1 ± 1.0** |

Parasites, wild type and transfected with the empty expression vector pX63 (*L. infantum*-pX63) or pX63-bcl-x$_L$ (*L. infantum*-Bcl-X$_L$), and HeLa cancer cells, wild type and transfected with the empty expression vector pSFFV (HeLa-pSFFV) or pSFFV-Bcl-x$_L$ (HeLa-Bcl-X$_L$), were incubated with 40 μM (*L. infantum*) or 10 μM (HeLa) edelfosine for 24 h, and then the percentage of hypodiploid cells (proportion of cells in the sub-G$_1$ cell cycle region) was determined by flow cytometry. Untreated control cells were run in parallel. Data shown are means ± SD of three independent experiments. Asterisks indicate values that are significantly different from drug-treated cells transfected with the empty vectors pX63 and pSFFV, respectively, at *P*<0.05 (*) and *P*<0.01 (**).
Lipid raft involvement in the uptake and cytotoxic action of edelfosine in *Leishmania* promastigotes and tumor cells

Because membrane rafts are a major target in the antitumor action of edelfosine [17–19, 36, 39], we analyzed, in a comparative way, the putative role of lipid rafts in the antileishmanial and anticancer activities of edelfosine. First, we found that raft disruption by preincubation of *L. panamensis* promastigotes with the cholesterol-depleting agent MCD [53], led to a partial, but statistically significant, inhibition of both edelfosine-induced cell death (Fig 6A) and edelfosine uptake (Fig 6B), suggesting a role for lipid rafts in *Leishmania* cell death. In addition, cholesterol depletion by MCD strongly inhibited edelfosine-induced cell death and drug uptake in the human T-cell leukemia Jurkat cells (Fig 6A and 6B). It is interesting to note that edelfosine uptake, assessed by the incorporation of \[^{3}H\]edelfosine, was higher in *Leishmania* promastigotes than in tumor cells.

Mitochondrial F\(_{0}\)F\(_{1}\)-ATP synthase is translocated into *L. panamensis* and leukemic Jurkat cell lipid rafts and modulates parasite and cancer cell killing upon edelfosine treatment

The anticancer activity of edelfosine has been shown to depend on the redistribution of lipid raft protein composition [17–19, 36, 38, 39, 54]. Because the above data indicated a remarkable parallelism between the mechanisms of action of edelfosine against *Leishmania* parasites and leukemic cells, we next isolated lipid rafts from untreated and edelfosine-treated *L. panamensis* promastigotes by fractionation of low-density detergent-insoluble membranes using discontinuous sucrose density gradient centrifugation. The position of lipid rafts in the sucrose gradients was determined by the presence of ganglioside GM1, detected using the GM1-specific ligand CTx B subunit (Fig 7A), which binds ganglioside GM1 [55], mainly found in rafts [56]. Following a proteomic study of the lipid raft fractions in *L. panamensis* promastigotes, we found a dramatic translocation to lipid rafts of mitochondrial F\(_{0}\)F\(_{1}\)-ATP synthase \(\beta\) subunit following drug incubation in *L. panamensis* promastigotes (Fig 7B and 7C). In addition, we found that oligomycin inhibited edelfosine-induced \(\Delta\Psi_{m}\) disruption and cell death in *Leishmania* (Fig 7D). These data suggest the involvement of F\(_{0}\)F\(_{1}\)-ATP synthase and its translocation to lipid rafts in the anti-*Leishmania* activity of edelfosine.

We also isolated lipid rafts from untreated and edelfosine-treated human T-cell leukemia Jurkat cells through sucrose gradient centrifugation, and the fractions enriched in lipid rafts were identified using the GM1-specific ligand CTx B subunit (Fig 8A). Similarly to *L. panamensis* parasites, a proteomic study of the lipid raft fractions from untreated and drug-treated cancer cells showed a major translocation of mitochondrial F\(_{0}\)F\(_{1}\)-ATP synthase \(\beta\) subunit to lipid rafts upon drug incubation in Jurkat cells (Fig 8B and 8C). Furthermore, oligomycin inhibited edelfosine-induced \(\Delta\Psi_{m}\) loss and cell death in Jurkat cells (Fig 8D).

Genetic abolishment of F\(_{0}\)F\(_{1}\)-ATP synthase activity blocks edelfosine cytotoxicity in *Saccharomyces cerevisiae* yeast

Because the above data suggested that F\(_{0}\)F\(_{1}\)-ATP synthase could play a major role in the cytotoxic activity of edelfosine against *Leishmania* promastigotes and cancer cells, we next sought to obtain genetic evidence for the role of this enzyme in edelfosine cytotoxicity by using yeast as a eukaryotic model organism. We used *Saccharomyces cerevisiae* yeast atp7\(\Delta\) mutant, with a deletion in the gene encoding for subunit d of the stator stalk of mitochondrial F\(_{0}\)F\(_{1}\)-ATP synthase, which is conserved in mammalian cells [57]. Since yeast is a facultative anaerobe and can survive with severely crippled mitochondrial function, we employed *S. cerevisiae*, which
has been previously shown to be sensitive to edelfosine [58], as a good model for genetic ablation assays. We chose the yeast *atp7* Δ mutant because ATP7 is essential for F$_{0}$F$_{1}$-ATP synthase function, but is not essential for growth in yeast. ATP7 deletion leads to a “petite” phenotype that is slow-growing and unable to survive on nonfermentable carbon sources [57].

We found that edelfosine inhibited wild-type yeast growth at 30 and 60 µM (Fig 9A), but *atp7*Δ mutant strain was resistant at these drug concentrations (Fig 9B). This edelfosine-resistant phenotype was reverted by transformation of the *atp7*Δ mutant with a centromeric
plasmid containing the \textit{atp7} wild-type gene (Fig 9C). Taken together, these results strongly support the involvement of \( \text{F}_0\text{F}_1\)-ATPase in the killing activity of edelfosine.

\textbf{Discussion}

Leishmaniasis therapy is currently far from satisfactory and search for novel druggable targets and new therapeutic approaches is urgently needed. APLs, originally developed as anticancer agents, have proved to show antileishmanial activity, but their mechanisms of action remain to be fully elucidated. Our data reported here indicate that the APL edelfosine is a promising drug against \textit{Leishmania} spp. parasites and tumor cells, and unveil common underlying proccesses in the killing activity of this APL on both \textit{Leishmania} and cancer cells. Edelfosine killed both \textit{Leishmania} promastigotes and amastigotes by an apoptosis-like process involving DNA

https://doi.org/10.1371/journal.pntd.0005805.g007
breakdown, and edelfosine oral treatment exerted a potent *in vivo* antileishmanial activity. We found here that edelfosine killed intracellular *Leishmania* amastigotes within macrophages, but spared the host cells. Results reported here point out a number of remarkable actions of edelfosine on macrophages, namely: a) normal BMM take up edelfosine, but unlike cancer cells, they are spared; b) edelfosine accumulates in the *Leishmania* amastigotes inside macrophages; c) edelfosine treatment, *in vitro* and *in vivo*, reduces the pro-inflammatory capacity of macrophages. These results suggest that edelfosine kills *Leishmania* parasites by acting directly on the parasite. Edelfosine and other APLs have been shown to act rather selectively on a wide range of malignant cells, mainly due to their predominant uptake by tumor cells [15, 17–19, 43, 59].
Fig 9. Edelfosine resistance of \( atp7^{\Delta} \) mutant in \textit{Saccharomyces cerevisiae} yeast. Growth curves of wild-type (BY4741) (A), \( ATP7 \) knock-out mutant (\( atp7^{\Delta} \)) (B) and the mutant strain harboring the corresponding cognate gene (\( atp7^{\Delta} + pRS416-ATP7 \)) (C) in SDC medium containing different concentrations of edelfosine. The cultures were carried out in duplicate and in at least three independent experiments. Data shown are mean values of three independent experiments. SD values were less than 10% of the mean values.

https://doi.org/10.1371/journal.pntd.0005805.g009
ability of macrophages to take up edelfosine constitutes the first evidence for the incorporation of edelfosine in a normal resting cell type at similar amounts as in cancer cells. This is of major importance in leishmaniasis because macrophages are the main host cells in Leishmania infection. We have previously found that the fluorescent edelfosine analog PTE-ET accumulated into naïve macrophages, especially around the nucleus, but once naïve macrophages were infected with Leishmania spp., an intense fluorescent signal was detected in the intracellular parasites [26]. These data, together with the findings reported here, indicate that edelfosine is taken up by naïve macrophages in significant amounts, and therefore it might affect some macrophage functions, such as the ones herein described, namely, a decrease in the generation of superoxide anion and nitric oxide, as well as in the production of IL-12+IL-18-induced IFN-γ.

Interestingly, when Leishmania parasites enter the macrophage, a substantial amount of drug is translocated to the sites where the parasites are located and then the drug is incorporated into the protozoa [26]. Thus, edelfosine could affect both macrophage functions and Leishmania survival. The finding that edelfosine diminishes the capacity of macrophages to mount an inflammatory response might be relevant, as severe inflammation at the site of infection leads to tissue destruction in leishmaniasis [60]. In this regard, edelfosine has also been reported to display a potent anti-inflammatory action through L-selectin shedding in human neutrophils, thus preventing neutrophil extravasation [31], and recent in vivo evidence further supports the anti-inflammatory and immunomodulatory effect of edelfosine [61–63]. Furthermore, edelfosine promotes apoptosis in mitogen-activated T lymphocytes [64]. On these grounds, edelfosine can affect in different ways the major leukocyte types involved in inflammation, namely neutrophils, macrophages and lymphocytes, thus leading eventually to decreased inflammatory responses.

We have also found here that edelfosine accumulates in mitochondria in both Leishmania parasites and tumor cells, leading to ∆Ψm loss and an apoptosis-like cell death. These results agree with recent reports showing a major location of different fluorescent edelfosine analogs in the mitochondria of cancer cells [37, 65]. Our data indicate that edelfosine induces firstly DNA fragmentation in the Leishmania kinetoplast-mitochondrion followed by nuclear DNA breakdown, while cell death in Leishmania parasites and tumor cells can be inhibited by protecting mitochondria through ectopic Bcl-XL expression. These results indicate a critical role of mitochondria in the edelfosine-induced cell killing mechanism in Leishmania parasites and tumor cells. Interestingly, the data reported here suggest that FoF1-ATP synthase plays a principal role in the edelfosine-induced killing activity in both Leishmania parasites and cancer cells. The involvement of the FoF1-ATP synthase in edelfosine cytotoxicity was further assessed through gene deletion experiments conducted in yeast, by showing that the lack of ATP7, which results in a defective FoF1-ATP synthase, inhibited edelfosine toxicity. Drug sensitivity was restored when ATP7Δ mutant yeast were transformed with the cognate wild-type gene. Thus, the results shown here strongly indicate by genetic and biochemical approaches that FoF1-ATP synthase is involved in the killing activity of edelfosine in both Leishmania parasites and human tumor cells.

The major role of mitochondria in edelfosine-induced Leishmania killing was further assessed by the generation of ROS in the parasite mitochondrion and the involvement of ROS in edelfosine-induced Leishmania promastigote cell death. Interestingly, edelfosine-induced ROS generation in Leishmania promastigotes was inhibited by oligomycin, an inhibitor of the Fo subunit of the mitochondrial FoF1-ATP synthase. Taken together, our data suggest a role for mitochondria and ROS generation in the execution of edelfosine-mediated apoptosis, and oligomycin is able to prevent edelfosine-induced ∆Ψm collapse and DNA degradation in both Leishmania parasites and cancer cells. These data highlight a major role of the Fo component of the FoF1-ATP synthase in the edelfosine-induced ∆Ψm dissipation, ROS generation and cell death. In this regard, the involvement of FoF1-ATP synthase in the apoptotic response induced
in glioblastoma cells by erucylphosphomocholine (ErPC3, Erufosine), another APL member, has been suggested [66]. Furthermore, oligomycin has also been reported to suppress TNF-induced apoptosis in human epithelioid carcinoma HeLa cells [67].

The mechanism by which F$_{0}$F$_{1}$-ATPase contributes to edelfosine-induced cell death remains to be established. F$_{0}$F$_{1}$-ATPase resides in the inner membrane of mitochondria and can pump protons in forward and reverse directions, either pumping protons into the mitochondrial matrix, flowing down their concentration gradient and leading to ATP generation, or pumping protons out of the mitochondrial matrix while hydrolyzing ATP. Because edelfosine affects membrane lipid organization, making membranes more fluid [68, 69], it might be suggested that edelfosine makes the outer membrane more porous, thus favoring the leakage of H$^{+}$ ions from the outer-inner intermembrane space into the cytosol, which leads to the dissipation of the proton gradient. As a consequence, the F$_{0}$F$_{1}$-ATP synthase could run in reverse, that is, hydrolyzing ATP and alkalinizing the matrix by proton extrusion. Because matrix alkalinization has been shown to cause opening of the mitochondria permeability transition pore [70], the F$_{0}$F$_{1}$-ATP synthase could facilitate cell death by this mechanism. This explanation has been previously proposed for the effect of oligomycin in inhibiting Bax-induced apoptosis in yeast and mammalian cells [71]. In this regard, we have found that edelfosine treatment led to a reduction in the ATP content of _L. panamensis_ promastigotes (Fig 10).

Furthermore, edelfosine has been reported to act through lipid rafts in human leukemic cancer cells [17–19, 22, 23, 36, 39], and recent evidence suggests a raft-mediated connection between the cell membrane and mitochondria in the action of edelfosine [20, 37, 38]. Here, we have found the involvement of lipid rafts in the antileishmanial activity of edelfosine, and edelfosine treatment led to a dramatic recruitment of mitochondrial F$_{0}$F$_{1}$-ATP synthase into rafts in both _Leishmania_ promastigotes and cancer cells. These findings are in line with the identification of lipid rafts in _Leishmania_ parasites [24], and with the impairment of miltefosine action against _L. donovani_ by membrane sterol depletion [72]. The results reported here suggest a redistribution of the F$_{0}$F$_{1}$-ATP synthase within the mitochondria or to additional raft domains in other cellular membranes following edelfosine treatment, thus altering the normal function of the enzyme and affecting cell viability. It could also be envisaged that the action of edelfosine

**Fig 10. Intracellular ATP measurements.** _L. panamensis_ promastigotes were treated with 10 μM edelfosine or 50 μM CCCP for different incubation times and processed for ATP intracellular content. Results are expressed as percentage of the amount of ATP found in untreated control cells. Data shown are means ± SD of three independent experiments.

https://doi.org/10.1371/journal.pntd.0005805.g010
on lipid rafts and mitochondria might underlie the inhibition of superoxide anion production in edelfosine-treated macrophages, generated by the NADPH-oxidase located at the macrophage cell membrane [73], and the enhancement of mitochondria-dependent ROS generation in drug-sensitive cells.

The results reported here highlight a major role for mitochondria and lipid rafts in the mechanism of action of edelfosine as both antileishmanial and anticancer drug. Nevertheless, cancer cells seem to be more dependable on lipid rafts than parasites, as shown by the relatively higher inhibition observed in drug uptake and drug-induced cell death when rafts were disrupted by sterol depletion (Fig 6). This putative mechanism of action involving mitochondria, and briefly depicted in Fig 11, seems to be common to both *Leishmania* parasites and tumor cells. The fact that protecting mitochondria by Bcl-XL ectopic expression leads to an inhibition in drug-induced cell death, further supports the major role of mitochondria and mitochondrial-mediated pathways in the killing activity of edelfosine in both *Leishmania* parasites and human cancer cells. Previous data on human cancer cells have demonstrated the involvement of mitochondria in the pro-apoptotic activity of edelfosine as an antitumor drug [16, 18, 20, 37, 38, 46, 74], and the results reported here extrapolate this notion to its leishmanicidal activity. In addition, the present results pinpoint the major role of ATP synthase in the killing activity of edelfosine against *Leishmania* parasites and tumor cells. We have previously found a link between lipid rafts and mitochondria in the mechanism of action of edelfosine [37, 38], suggesting an edelfosine-mediated redistribution of lipid rafts from the plasma membrane to mitochondria [37, 38]. The results reported here indicate that F$_{0}$F$_{1}$-ATPase is either translocated to cell surface lipid rafts or to raft domains present in mitochondria. A number of reports have shown the presence of raft-localized F$_{0}$F$_{1}$-ATP synthase at the cell surface of several cell types, having been proposed to act as a receptor for different ligands, a proton channel, or a modulator of extracellular ATP levels, involved in numerous biological processes through still unclear mechanisms [75–81]. Our results cannot discern between a cell surface and a mitochondrial localization for the raft-associated F$_{0}$F$_{1}$-ATP synthase following edelfosine treatment reported here. Thus, a putative translocation of the mitochondrial F$_{0}$F$_{1}$-ATP synthase to the cell surface cannot be ruled out at the moment, and additional experimental approaches should be applied to elucidate the prevailing localization of raft-located F$_{0}$F$_{1}$-ATP synthase. However, our present data indicating an accumulation of the ether lipid in the mitochondria of both *Leishmania* parasites and cancer cells, lead us to suggest that a plausible mechanism could involve the translocation of edelfosine from the plasma membrane to the mitochondria where it would ultimately exert its cytotoxic activity promoting the accumulation of F$_{0}$F$_{1}$-ATP synthase into mitochondrial rafts, and leading to the dissipation of the mitochondrial membrane potential, ROS generation, and eventually cell demise (Fig 11). The fact that kinetoplast-mitochondrion was the first organelle where ROS metabolites were generated and DNA was broken down, preceding nuclear DNA fragmentation, points out the critical role of mitochondria as a major target in the search for effective drugs to treat leishmaniasis. It is tempting to suggest that a link between lipid rafts and mitochondria could lead to interesting hints to unveil a novel framework in both *Leishmania* and cancer therapy. The present data also indicate that our insight on how edelfosine works as an antitumor drug can be of great aid to and give valuable information to uncover the mechanism of action of its leishmanicidal activity, which could be hypothetically extrapolated to other antileishmanial drugs, and might be of inspiration to further identify potential common therapeutic targets in cancer and leishmaniasis.

Taken together, our data indicate that the edelfosine antileishmanial and antitumor mechanisms of action share similar molecular processes, involving mitochondria, lipid rafts and F$_{0}$F$_{1}$-ATPase. This study provides a molecular explanation on how the antitumor drug
Edelfosine acts as an antileishmanial agent, and highlights that mitochondria, lipid rafts and F$_{0}$F$_{1}$-ATPase act as major players in cell death modulation, opening new avenues for therapeutic intervention in leishmaniasis and cancer. Our results show that the ether phospholipid edelfosine can be a promising orally administered therapeutic agent and a lead compound in the search for novel and much-needed antileishmanial agents, and identify lipid rafts, mitochondria and F$_{0}$F$_{1}$-ATPase as appealing new antileishmanial targets. Furthermore, the results shown here indicate that edelfosine is very effective in killing different species of Leishmania parasites, as well as in distinct developmental stages, such as promastigotes and amastigotes. Interestingly, recent data have shown an increasing rate of relapse against miltefosine and a decline in its efficacy [82–85], which could correspond to the readiness in acquiring experimental drug resistance to miltefosine in vitro [86–88]. We have previously shown that edelfosine is less prone to lead to drug resistance development than miltefosine, and displays a higher antileishmanial activity than miltefosine against a wide variety of Leishmania spp. [26].

Fig 11. Schematic model of mitochondria involvement in the killing activity of edelfosine against Leishmania parasites and tumor cells. This is a schematic diagram to portray one currently plausible mechanism of how edelfosine induces cell death in Leishmania parasites and tumor cells through its main mitochondrial localization in both biological systems. Protection of mitochondria by Bcl-X$_L$ ectopic expression restrains cell death. See text for details.

https://doi.org/10.1371/journal.pntd.0005805.g011
Thus the potent leishmanicidal activity of edelfosine, together with its low toxicity profile [31], warrants further clinical evaluation for this ether lipid as a possible therapeutic agent against different forms of leishmaniasis.

Acknowledgments
We are grateful to Samuel Ogueta, Nieves Ibarrola and Rosa Dégano, members of the CIC-Proteomics Laboratory, for technical support in proteomic analysis. We are thankful to P. Kropf, B.G. Sierra, J. López-Abán, H. Zhang, and M. Reis-Sobreiro for assistance in the initial stages of this study.

Author Contributions
Conceptualization: Janny A. Villa-Pulgarín, Consuelo Gajate, Faustino Mollinedo.
Funding acquisition: Faustino Mollinedo.
Investigation: Janny A. Villa-Pulgarín, Consuelo Gajate, Javier Botet, Alberto Jimenez, Nicole Justies, Rubén E. Varela-M, Álvaro Cuesta-Marbán, Ingrid Müller, Manuel Modolell, José L. Revuelta, Faustino Mollinedo.
Methodology: Janny A. Villa-Pulgarín, Consuelo Gajate, Rubén E. Varela-M, Ingrid Müller, Manuel Modolell, José L. Revuelta, Faustino Mollinedo.
Project administration: Faustino Mollinedo.
Supervision: Faustino Mollinedo.
Validation: Janny A. Villa-Pulgarín, Consuelo Gajate, Manuel Modolell, José L. Revuelta, Faustino Mollinedo.
Visualization: Janny A. Villa-Pulgarín, José L. Revuelta, Faustino Mollinedo.
Writing – original draft: Faustino Mollinedo.
Writing – review & editing: Faustino Mollinedo.

References
1. Murray HW, Berman JD, Davies CR and Saravia NG. Advances in leishmaniasis. Lancet. 2005; 366: 1561–77.
2. WHO. Control of the leishmaniases. World Health Organ Tech Rep Ser. 2010; 949: 1–186.
3. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7: e35671. https://doi.org/10.1371/journal.pone.0035671 PMID: 22693548
4. Mollinedo F, Janssen H, de la Iglesia-Vicente J, Villa-Pulgarín JA and Calafat J. Selective fusion of azurophilic granules with Leishmania-containing phagosomes in human neutrophils. J Biol Chem. 2010; 285: 34528–36. https://doi.org/10.1074/jbc.M110.125302 PMID: 20801889
5. Alexander J, Satoskar AR and Russell DG. Leishmania species: models of intracellular parasitism. J Cell Sci. 1999; 112 Pt 18: 2993–3002.
6. Gajate C and Mollinedo F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH₃ (Edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab. 2002; 3: 491–525. PMID: 12369895
7. Mollinedo F. Antitumor ether lipids: proapoptotic agents with multiple therapeutic indications. Expert Opin Ther Patents. 2007; 17: 365–405.
8. Mollinedo F. Editorial: Antitumor alkylphospholipid analogs: a promising and growing family of synthetic cell membrane-targeting molecules for cancer treatment. Anticancer Agents Med Chem. 2014; 14: 495–8. PMID: 24628231
9. Leonard R, Hardy J, van Tienhoven G, Houston S, Simmonds P, David M, et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol. 2001; 19: 4150–9. https://doi.org/10.1200/JCO.2001.19.21.4150 PMID: 11689583

10. Dorlo TP, Balasegaram M, Beijnen JH and de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012; 67: 2576–97. https://doi.org/10.1093/jac/dks275 PMID: 2283634

11. Verma NK and Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother. 2004; 48: 3010–5. https://doi.org/10.1128/AAC.48.8.3010-3015.2004 PMID: 15273114

12. Paris C, Loiseau PM, Bories C and Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother. 2004; 48: 852–9. https://doi.org/10.1128/AAC.48.3.852-859.2004 PMID: 14982775

13. Lux H, Heise N, Klenner T, Hart D and Opperdorfer FR. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol. 2000; 111: 1–14. PMID: 11087912

14. Moreira RA, Mendanha SA, Fernandes KS, Matos GG, Almaro L, Dorta ML, et al. Miltefosine increases lipid and protein dynamics in Leishmania amazonensis membranes at concentrations similar to those needed for cytotoxicity activity. Antimicrob Agents Chemother. 2014; 58: 308–10. https://doi.org/10.1128/AAC.01322-13 PMID: 24614389

15. Mollinedo F, Fernandez-Luna JL, Gajate C, Martin-Martin B, Benito A, Martinez-Dalmau R, et al. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-xL. Cancer Res. 1997; 57: 1320–8. PMID: 9102220

16. Gajate C, Santos-Benedit AM, Macho A, Lazaro M, Hernandez-De Rojas A, Modolell M, et al. Involvement of mitochondria and caspase-3 in ET-18-OCH3-induced apoptosis of human leukemic cells. Int J Cancer. 2000; 86: 208–18. PMID: 10738248

17. Gajate C, Del Canto-Janez E, Acuna AU, Arnat-Guerri F, Geijo E, Santos-Benedit AM, et al. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med. 2004; 200: 353–65. https://doi.org/10.1084/jem.20040213 PMID: 15289504

18. Gajate C and Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood. 2007; 109: 711–9. https://doi.org/10.1182/blood-2006-04-016824 PMID: 17003375

19. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estrella-Hermoso de Mendoza A, Villa-Pulgarin JA, Campanero MA, et al. Lipid raft-targeted therapy in multiple myeloma. Oncogene. 2010; 29: 3748–57. https://doi.org/10.1038/onc.2010.131 PMID: 20418917

20. Gajate C and Mollinedo F. Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine. Anticancer Agents Med Chem. 2014; 14: 509–27. PMID: 24628241

21. Mollinedo F and Gajate C. Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy. Future Oncol. 2010; 6: 811–21. https://doi.org/10.2217/fon.10.34 PMID: 20465392

22. Gajate C and Mollinedo F. Lipid rafts and raft-mediated supramolecular entities in the regulation of CD95 death receptor apoptotic signaling. Apoptosis. 2015; 20: 584–606. https://doi.org/10.1007/s10495-015-1104-6 PMID: 25702154

23. Gajate C and Mollinedo F. Lipid raft-mediated Fas/CD95 apoptotic signaling in leukemic cells and normal leukocytes and therapeutic implications. J Leukoc Biol. 2015; 98: 739–59. https://doi.org/10.1182/jlb.2MR0215-055R PMID: 26246489

24. Denny PW and Smith DF. Rafts and sphingolipid biosynthesis in the kinetoplastid parasitic protozoa. Mol Microbiol. 2004; 53: 725–33. https://doi.org/10.1111/j.1365-2958.2004.04208.x PMID: 15255887

25. Varela MR, Munoz DL, Robledo SM, Kolli BK, Dutta S, Chang KP, et al. Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug. Exp Parasitol. 2008; 122: 134–9. https://doi.org/10.1016/j.exppara.2008.02.012 PMID: 19393871

26. Varela-M RE, Villa-Pulgarin JA, Yepes E, Muller I, Modolell M, Munoz DL, et al. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SBV-resistant parasites. PLoS Negl Trop Dis. 2012; 6: e1612. https://doi.org/10.1371/journal.pntd.0001612 PMID: 22506088

27. Taylor VM, Munoz DL, Cedeno DL, Velez ID, Jones MA and Robledo SM. Leishmania tarentolae: utility as an in vitro model for screening of antileishmanial agents. Exp Parasitol. 2010; 126: 471–5. https://doi.org/10.1016/j.exppara.2010.05.016 PMID: 20685203
28. Giaever G, Chu AM, Ni L, Connelly C, Riles L, Veronneau S, et al. Functional profiling of the *Saccharomyces cerevisiae* genome. Nature. 2002; 418: 387–91. https://doi.org/10.1038/nature00935 PMID: 12140549

29. Alzate JF, Alvarez-Barrientos A, Gonzalez VM and Jimenez-Ruiz A. Heat-induced programmed cell death in *Leishmania infantum* is reverted by Bcl-X<sub>L</sub> expression. Apoptosis. 2006; 11: 161–71. https://doi.org/10.1007/s10495-006-4570-z PMID: 16502255

30. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood. 2005; 105: 2549–56. https://doi.org/10.1182/blood-2004-07-2521 PMID: 15546957

31. Mollinedo F, Gajate C, Morales AI, del Canto-Janez E, Justies N, Collia F, et al. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J Pharmacol Exp Ther. 2009; 329: 439–49. https://doi.org/10.1124/jpet.108.148254 PMID: 19244550

32. Modolell M, Eichmann K and Soler G. Oxidation of N(G)-hydroxy-L-arginine to nitric oxide mediated by respiratory burst: an alternative pathway to NO synthesis. FEBS Lett. 1997; 401: 123–6. PMID: 9013871

33. Kricka LJ. Clinical and biochemical applications of luciferases and luciferins. Anal Biochem. 1988; 175: 14–21. PMID: 3072882

34. Henao HH, Osorio Y, Saravia NG, Gomez A and Travi B. Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application. Biomedica. 2004; 24: 393–402. PMID: 15678803

35. Gajate C, Fonteriz RI, Cabaner C, Alvarez-Novés G, Alvarez-Rodríguez Y, Modolell M, et al. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer. 2000; 85: 674–82. PMID: 10699948

36. Gajate C, Gonzalez-Camacho F and Mollinedo F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS ONE. 2009; 4: e5044. https://doi.org/10.1371/journal.pone.0005044 PMID: 19352436

37. Mollinedo F, Fernandez M, Hornillos V, Delgado J, Amat-Guerr F, Acuna AU, et al. Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria. Cell Death Dis. 2011; 2: e158. https://doi.org/10.1038/cddis.2011.41 PMID: 21593790

38. Gajate C, Gonzalez-Camacho F and Mollinedo F. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem Biophys Res Commun. 2009; 380: 780–4. https://doi.org/10.1016/j.bbrc.2009.01.147 PMID: 19338752

39. Gajate C and Mollinedo F. The antitumor ether lipid ET-18-OCH<sub>3</sub> induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood. 2001; 98: 3860–3. PMID: 11739199

40. Shevchenko A, Wilm M, Vorm O and Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996; 68: 850–8. PMID: 8779443

41. Perkins DN, Pappin DJ, Creasy DM and Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999; 20: 3551–67. https://doi.org/10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-P PMID: 10612281

42. Estella-Hermoso de Mendoza A, Campanero MA, de la Iglesia-Vicente J, Gajate C, Mollinedo F and Blanco-Prieto MJ. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res. 2009; 15: 858–64. https://doi.org/10.1158/1078-0432.CCR-08-1654 PMID: 19188156

43. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, de Frias M, et al. In vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res. 2010; 16: 2046–54. https://doi.org/10.1158/1078-0432.CCR-09-2456 PMID: 20233887

44. Gajate C, Santos-Benedit A, Modolell M and Mollinedo F. Involvement of c-Jun NH<sub>2</sub>-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycerol-3-phosphocholine. Mol Pharmacol. 1998; 53: 602–12. PMID: 9547349

45. Nieto-Miguel T, Gajate C and Mollinedo F. Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells. J Biol Chem. 2006; 281: 14833–40. https://doi.org/10.1074/jbc.M511251200 PMID: 16540473

46. Gajate C, Matos-da-Silva M, Dakir EL, Fonteriz RI, Alvarez J and Mollinedo F. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum. Oncogene. 2012; 31: 2627–39. https://doi.org/10.1038/onc.2011.446 PMID: 22056873
47. Sacks DL and Melby PC. Animal models for the analysis of immune responses to leishmaniasis. Curr Protoc Immunol. 2001;Chapter 19: Unit 19.2.

48. Quesada E, Delgado J, Gajate C, Mollinedo F, Acuna AU and Amat-Guerr F. Fluorescent phenylpropylene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells. J Med Chem. 2004; 47: 5333–5. https://doi.org/10.1021/jm049808a PMID: 15481970

49. Saugar JM, Delgado J, Hormillos V, Luque-Ortega JR, Amat-Guerr F, Acuna AU, et al. Synthesis and biological evaluation of fluorescent leishmanicidal analogues of hexadecylphosphocholine (miltefosine) as probes of antiparasite mechanisms. J Med Chem. 2007; 50: 5994–6003. https://doi.org/10.1021/jm070595+ PMID: 17973359

50. Di Lisa F and Bernardi P. Mitochondrial function as a determinant of recovery or death in cell response to injury. Mol Cell Biochem. 1998; 184: 379–91. PMID: 9746332

51. Wallace KB and Starkov AA. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol. 2000; 40: 353–88. https://doi.org/10.1146/annurev.pharmtox.40.1.353 PMID: 10836141

52. Penefsky HS. Mechanism of inhibition of mitochondrial ATP synthase by dicyclohexylcarbodiimide and oligomycin: relationship to ATP synthesis. Proc Natl Acad Sci U S A. 1985; 82: 1589–93. PMID: 2858849

53. Christian AE, Haynes MP, Phillips MC and Rothblat GH. Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res. 1997; 38: 2264–72. PMID: 9392424

54. Reis-Sobroiro M, Roue G, Moros A, Gajate C, de la Iglesia-Vicente J, Colomer D, et al. Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J. 2013; 3: e118. https://doi.org/10.1038/bjc.2013.15 PMID: 23727661

55. Schon A and Freire E. Thermodynamics of intersubunit interactions in cholera toxin upon binding to the oligosaccharide portion of its cell surface receptor, ganglioside GM1. Biochemistry. 1989; 28: 5019–24. https://doi.org/10.1038/bcj.2013.15 PMID: 23727661

56. Norais N, Prome D and Velours J. ATP synthase of yeast mitochondria. Characterization of subunit d and sequence analysis of the structural gene ATP7. J Biol Chem. 1991; 266: 16541–9. PMID: 1832157

57. Cuesta-Marban A, Botet J, Czyz O, Cacharro LM, Gajate C, Hornillos V, et al. Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast. J Biol Chem. 2013; 288: 8405–18. https://doi.org/10.1074/jbc.M112.425769 PMID: 23335509

58. Weichert JP, Clark PA, Kandela IK, Vaccaro AM, Clarke W, Longino MA, et al. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med. 2014; 6: 240ra75. https://doi.org/10.1126/scitranslmed.3007646 PMID: 24920661

59. Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC and von Stebut E. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol. 2009; 182: 3039–46. https://doi.org/10.4049/jimmunol.0713598 PMID: 19234200

60. Abramowski P, Otto B and Martin R. The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response. PLoS One. 2014; 9: e91970. https://doi.org/10.1371/journal.pone.0091970 PMID: 24667731

61. Abramowski P, Steinbach K, Zander AR and Martin R. Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014; 274: 111–24. https://doi.org/10.1016/j.jneuroim.2014.07.007 PMID: 25086877

62. Yepes E, Varela MR, Lopez-Aban J, Rojas-Caraballo J, Muro A and Mollinedo F. Inhibition of granulomatous inflammation and prophylactic treatment of schistosomiasis with a combination of edelfosine and praziquantel. PLoS Negl Trop Dis. 2015; 9: e0003893. https://doi.org/10.1371/journal.pntd.0003893 PMID: 26191954

63. Cabanel C, Gajate C, Macho A, Munoz E, Modolell M and Mollinedo F. Induction of apoptosis in human mitogen-activated peripheral blood T- lymphocytes by the ether phospholipid ET-18-OCH<sub>3</sub>: involvement of the Fas receptor/ligand system. Br J Pharmacol. 1999; 127: 813–25. https://doi.org/10.1038/sj.bjp.0702606 PMID: 10434387

64. Kuerschner L, Richter D, Hannibal-Bach HK, Gaebler A, Shevchenko A, Eising CS, et al. Exogenous ether lipids predominantly target mitochondria. PLoS ONE. 2012; 7: e31342. https://doi.org/10.1371/journal.pone.0031342 PMID: 22348073

65. Veenman L, Alten J, Linnenmannstons K, Shandalov Y, Zeno S, Lakomek M, et al. Potential involvement of F<sub>0</sub>F<sub>1</sub>-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines: a mechanism for induction of apoptosis via the 18 kDa mitochondrial translocator protein. Apoptosis. 2010; 15: 753–68. https://doi.org/10.1007/s10495-010-0460-5 PMID: 20107899
67. Shchepina LA, Pletjushkina OY, Avetisyan AV, Bakeeva LE, Fetisova EK, Izyumov DS, et al. Oligomycin, inhibitor of the F\textsubscript{0} part of H\textsuperscript{+}-ATP-synthase, suppresses the TNF-induced apoptosis. Oncogene. 2002; 21: 8149–57. https://doi.org/10.1038/sj.onc.1206053 PMID: 12444550

68. Ausili A, Torrecillas A, Aranda FJ, Molineno F, Gajate C, Corbalan-Garcia S, et al. Edelfosine is incorporated into rafts and alters their organization. J Phys Chem B. 2008; 112: 11643–11654. https://doi.org/10.1021/jp0802165n PMID: 18712919

69. Castro BM, Fedorov A, Hornillos V, Delgado J, Acuna AU, Molineno F, et al. Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids. J Phys Chem B. 2013; 117: 7929–40. https://doi.org/10.1021/jp401407d PMID: 23738749

70. Bernardi P, Vassanelli S, Veronese P, Colonna R, Szabo I and Zoratti M. Modulation of the mitochondrial permeability transition pore. Effect of protons and divalent cations. J Biol Chem. 1992; 267: 2934–9. PMID: 1737749

71. Matsuyama S, Xu Q, Velours J and Reed JC. The mitochondrial F\textsubscript{1}F\textsubscript{0}-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell. 1998; 1: 327–36. PMID: 9660917

72. Saint-Pierre-Chazalet M, Ben Brahim M, Le Moyec L, Bories C, Rakotomanga M and Loiseau PM. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes. J Antimicrob Chemother. 2009; 64: 993–1001. https://doi.org/10.1093/jac/dkp321 PMID: 19749205

73. Casbon AJ, Allen LA, Dunn KW and Dinauer MC. Macrophage NADPH oxidase flavocytochrome B localizes to the plasma membrane and Rab11-positive recycling endosomes. J Immunol. 2009; 182: 2325–39. https://doi.org/10.4049/jimmunol.0803476 PMID: 19201887

74. Nieto-Miguel T, Fonteriz RI, Vay L, Gajate C, Lopez-Hernandez S and Molineno F. Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. Cancer Res. 2007; 67: 10368–10378. https://doi.org/10.1158/0008-5472.CAN-07-0278 PMID: 17974980

75. Das B, Mondragon MO, Sadeghian M, Hatcher VB and Norin AJ. A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H\textsuperscript{+} transporting ATP synthase on the surface of tumor cell lines. J Exp Med. 1994; 180: 273–81. PMID: 8006588

76. Bae TJ, Kim MS, Kim JW, Choo HJ, Lee JW, et al. Lipid raft proteome reveals ATP synthase complex in the cell surface. Proteomics. 2004; 4: 3536–48. https://doi.org/10.1002/pmic.200400952 PMID: 15378739

77. Ma Z, Cao M, Liu Y, He Y, Wang Y, Yang C, et al. Mitochondrial F\textsubscript{1}F\textsubscript{0}-ATP synthase translocates to cell surface in hepatocytes and has high activity in tumor-like acidic and hypoxic environment. Acta Biochim Biophys Sin (Shanghai). 2010; 42: 530–7.

78. Kim BW, Lee CS, Yi JS, Lee JH, Cho JW, et al. Lipid raft proteome reveals that oxidative phosphorylation system is associated with the plasma membrane. Expert Rev Proteomics. 2010; 7: 849–66. https://doi.org/10.1586/epr.10.87 PMID: 21142887

79. Kawai Y, Kaidoh M, Yokoyama Y and Ohhashi T. Cell surface F\textsubscript{1}F\textsubscript{0} ATP synthase contributes to interstitial flow-mediated development of the acidic microenvironment in tumor tissues. Am J Physiol Cell Physiol. 2013; 305: C1139–50. https://doi.org/10.1152/ajpcell.00199.2013 PMID: 24067918

80. Wang WJ, Shi XX, Liu YW, He YQ, Wang YZ, Yang CX, et al. The mechanism underlying the effects of the cell surface ATP synthase on the regulation of intracellular acidification during acidosis. J Cell Biochem. 2013; 114: 1695–703. https://doi.org/10.1002/jcb.24511 PMID: 23386430

81. Allen-Worthington K, Xie J, Brown JL, Edmunson AM, Dowling A, Navratil AM, et al. The F\textsubscript{0}F\textsubscript{1} synthase complex localizes to membrane rafts in gonadotrope cells. Mol Endocrinol. 2016; 30: 996–1011. https://doi.org/10.1210/me.2015-1324 PMID: 27482602

82. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis. 2012; 55: 543–50. https://doi.org/10.1093/cid/cis474 PMID: 22573856

83. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, et al. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfestation, or non-compliance. Clin Infect Dis. 2013; 56: 1530–8. https://doi.org/10.1093/cid/cit422 PMID: 23429558

84. Ramesh V, Singh R, Avishek K, Verma A, Deep DK, Verma S, et al. Decline in clinical efficacy of oral miltefosine in treatment of post kala-azar dermal leishmaniasis (PKDL) in India. PLoS Negl Trop Dis. 2015; 9: e0004093. https://doi.org/10.1371/journal.pntd.0004093 PMID: 26492039

85. Deep DK, Singh R, Bhandari V, Verma A, Sharma V, Wajid S, et al. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. PLoS Negl Trop Dis. 2017; 11: e0005641. https://doi.org/10.1371/journal.pntd.0005641 PMID: 28675060
86. Perez-Victoria FJ, Castany S and Gamarro F. *Leishmania donovani* resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother. 2003; 47: 2397–403. https://doi.org/10.1128/AAC.47.8.2397-2403.2003 PMID: 12878496

87. Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, Croft SL, Sundar S, Castanys S, et al. Mechanisms of experimental resistance of *Leishmania* to miltefosine: Implications for clinical use. Drug Resist Updat. 2006; 9: 26–39. https://doi.org/10.1016/j.drup.2006.04.001 PMID: 16814199

88. Kulshrestha A, Sharma V, Singh R and Salotra P. Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant *Leishmania donovani*. Parasitol Res. 2014; 113: 1171–84. https://doi.org/10.1007/s00436-014-3755-6 PMID: 24449447